British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
- 1 April 1997
- journal article
- consensus statement
- Published by Elsevier BV in The Lancet
- Vol. 349 (9058), 1086-1092
- https://doi.org/10.1016/s0140-6736(96)12073-0
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- Antiretroviral Therapy for HIV Infection in 1996JAMA, 1996
- Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Antiretroviral-Naive PatientsJAMA, 1996
- Virologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and Zalcitabine or Didanosine Compared with Zidovudine MonotherapyThe Journal of Infectious Diseases, 1996
- Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic MillimeterNew England Journal of Medicine, 1995
- Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (−)-2′,3′-dideoxy-3′-thiacytidineAntiviral Research, 1995
- Didanosine and ACTG 116AThe Lancet, 1993